NAGORSEN, DIRK,KUFER, PETER,ZUGMAIER, GERHARD,BAEUERLE, PATRICK
申请号：
PL10771102
公开号：
PL2493503T3
申请日:
2010.10.27
申请国别(地区):
PL
年份:
2016
代理人:
摘要：
Provided herein is a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19.times.CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient.
